Actelion’s Tracleer Hangs On Against Label-Dampened Letairis
This article was originally published in The Pink Sheet Daily
Executive Summary
Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.